Kinase Inhibitors

A novel compound represented by the following general formula:

• wherein X is selected from the group consisting of C═O, C═S, CR4R5, O, S, NH, and NR4;
• Z is selected from the group consisting of hydrogen, C1 to C8 alkyl, phenyl, hydroxymethyl, —CH2—N(—CH2CH2WCH2CH2—), COCH3, CH2CH2OH, and CH2CH2CH2OH;
• W is selected from the group consisting of O, S, CH2 and NCH3;
• R1 is selected from the group consisting of hydrogen and CH3;
• R3 is selected from the group consisting of hydrogen, halogen, C1 to C8 alkyl, phenyl, hydroxymethyl, COCH3, CH2CH2OH, CH2CH2CH2OH and [C(R2)2]cN(R2)2, wherein R2 is selected from the group consisting of hydrogen, halogen, NO2, CN, C1 to C4 alkyl or aryl, and N(R2)2 may form a 3 to 7 membered heterocyclic ring, and said heterocyclic ring may be substituted with one or more of R2;
• and [C(R2)2]c may form a 3 to 7 membered carbocyclic or heterocyclic ring;
• R4 and R5 may be selected from the group consisting of hydrogen, halogen, NO2, CN, C1 to O8 alkyl and aryl;
• or CR4R5 may form a 3 to 7 membered carbocyclic or heterocyclic ring;
• A is 3 to 7 membered heterocyclic ring;
• X′ is selected from the group consisting of
• and
• B may be selected from the group consisting of hydrogen, hydroxy, C1 to C8 alkyl, aryl and CR4R5 wherein CR4R5 may form a 3 to 7 membered carbocyclic or heterocyclic ring;
• a is 0 or an integer of from 1 to 5, preferably 1 to 3;
• c is 0 or an integer of from 1 to 4,
• d is an integer of from 2 to 5;
• the wavy line represents a E or Z bond and pharmaceutically acceptable salts thereof.